T. Rowe Price Associates
MLTX icon

T. Rowe Price Associates’s MoonLake Immunotherapeutics MLTX Stock Holding History

T. Rowe Price Associates’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.3M Sell
1,041,527
-253,334
-20% -$4.59M ﹤0.01% 1147
2026
Q1 		$24.1M Buy
1,294,861
+335,308
+35% +$5.55M ﹤0.01% 994
2025
Q4 		$12.6M Buy
959,553
+136,596
+17% +$1.61M ﹤0.01% 1181
2025
Q3 		$5.9M Sell
822,957
-1,790,276
-69% -$93.3M ﹤0.01% 1351
2025
Q2 		$123M Sell
2,613,233
-360,597
-12% -$14.7M 0.01% 529
2025
Q1 		$116M Sell
2,973,830
-369,813
-11% -$15.9M 0.01% 525
2024
Q4 		$181M Buy
3,343,643
+363,394
+12% +$18.6M 0.02% 451
2024
Q3 		$150M Buy
2,980,249
+418,737
+16% +$19.6M 0.02% 491
2024
Q2 		$113M Buy
2,561,512
+425,629
+20% +$18M 0.01% 525
2024
Q1 		$107M Sell
2,135,883
-178,129
-8% -$9.66M 0.01% 534
2023
Q4 		$140M Buy
2,314,012
+196,144
+9% +$10.1M 0.02% 485
2023
Q3 		$121M Buy
2,117,868
+174,812
+9% +$9.65M 0.02% 480
2023
Q2 		$99.1M Buy
1,943,056
+1,112,150
+134% +$29.9M 0.01% 528
2023
Q1 		$17.8M Buy
830,906
+8,305
+1% +$140K ﹤0.01% 945
2022
Q4 		$8.64M Sell
822,601
-46,787
-5% -$416K ﹤0.01% 1080
2022
Q3 		$6.92M Sell
869,388
-1,136
-0.1% -$8.03K ﹤0.01% 1140
2022
Q2 		$4.44M Buy
870,524
+304,333
+54% +$1.91M ﹤0.01% 1437
2022
Q1 		$6.29M Sell
566,191
-180,671
-24% -$1.8M ﹤0.01% 1428
2021
Q4 		$7.39M Sell
746,862
-9,441
-1% -$93.8K ﹤0.01% 1453
2021
Q3 		$7.46M Hold
756,303
– – ﹤0.01% 1462
2021
Q2 		$7.81M Sell
756,303
-35,982
-5% -$365K ﹤0.01% 1447
2021
Q1 		$8.11M Buy
792,285
+4,500
+0.6% +$49.6K ﹤0.01% 1422
2020
Q4 		$8.53M Buy
+787,785
New +$8.36M ﹤0.01% 1366

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

T. Rowe Price Associates's MLTX Position: Q2 2026 in Review

T. Rowe Price Associates reduced its MoonLake Immunotherapeutics (MLTX) stake by 20% in Q2 2026, selling an estimated $4.59M and leaving 1,041,527 shares worth $20.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1147.

T. Rowe Price Associates first reported a position in MLTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $181M in Q4 2024. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • T. Rowe Price Associates held 1,041,527 shares of MoonLake Immunotherapeutics worth $20.3M as of Q2 2026.
  • T. Rowe Price Associates sold 253,334 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $4.59M.
  • MoonLake Immunotherapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1147 holding.
  • T. Rowe Price Associates first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 23 quarters since.
  • T. Rowe Price Associates's MoonLake Immunotherapeutics position peaked at $181M in Q4 2024.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.